Patents by Inventor Timothy M. Thomson

Timothy M. Thomson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11919887
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: March 5, 2024
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Steven John Durrant, Nadia M. Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
  • Patent number: 4798790
    Abstract: Monoclonal antibody TA99, which specifically binds to a pigmentation associated antigen present on melanoma cells is described. Additionally, the hybridoma cell line deposited with the ATCC under Accession Number HB 8704 from which the antibody is derived, as well as methods for using the antibody are described.
    Type: Grant
    Filed: July 18, 1985
    Date of Patent: January 17, 1989
    Assignee: Sloan-Kettering Institute
    Inventors: Timothy M. Thomson, M. Jules Mattes, Lloyd J. Old, Kenneth O. Lloyd, Linda Roux
  • Patent number: 4727021
    Abstract: Human monoclonal antibodies (HmAbs) capable of reacting with cytokeratin are disclosed. It has been found that HmAbs De8, M54, M307, Hull, C29, Hu22 and Pa24 may be used to detect these cytoskeletal proteins in various cells. By means of these HmAbs the embryological origin of cells may be determined. This information may be used to determine the possible tissue source of metastasized tumors and greatly affects the management of these cancers.
    Type: Grant
    Filed: June 1, 1984
    Date of Patent: February 23, 1988
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Richard J. Cote, Timothy M. Thomson, Alan N. Houghton, Herbert F. Oettgen, Lloyd J. Old
  • Patent number: 4695538
    Abstract: Human monoclonal antibodies (HmAbs) capable of reacting with cell surface antigens and intracellular components are disclosed. It has been found that HmAbs Ev248, Ch-5, Ch-13, Te-39, Hu44, Ge-1, Gr-431, Gr169 and Sp909 may be used to detect these antigens in various cells. By means of these HmAbs malignant cells may be determined. This information may be used to screen metastasized tumors and primary tumors for tissue source and greatly affects the management of these cancers.
    Type: Grant
    Filed: June 1, 1984
    Date of Patent: September 22, 1987
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Richard J. Cote, Timothy M. Thomson, Alan N. Houghton, Herbert F. Oettgen, Lloyd J. Old, Carlos C. Cardo
  • Patent number: 4591572
    Abstract: The present invention concerns an autologous precipitating antibody and the gp70 pigment-associated antigen on melanoma cells which it recognizes. The antibody is useful in detecting pigmented melanoma cells in excised specimen, serum or urine.
    Type: Grant
    Filed: April 1, 1983
    Date of Patent: May 27, 1986
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: M. Jules Mattes, Timothy M. Thomson, Lloyd J. Old, Kenneth O. Lloyd